Should I buy or sell Hikma Pharmaceuticals stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Hikma Pharmaceuticals in the last twelve months. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" HIK shares. View HIK analyst ratings or view top-rated stocks .

What is Hikma Pharmaceuticals' stock price target for 2024?

6 equities research analysts have issued 1-year price targets for Hikma Pharmaceuticals' stock. Their HIK share price targets range from GBX 2,000 to GBX 2,150. On average, they predict the company's stock price to reach GBX 2,068.75 in the next year. This suggests a possible upside of 15.6% from the stock's current price. View analysts price targets for HIK or view top-rated stocks among Wall Street analysts .

How have HIK shares performed in 2024?

Hikma Pharmaceuticals' stock was trading at GBX 1,789 at the beginning of the year. Since then, HIK stock has increased by 0.0% and is now trading at GBX 1,789. View the best growth stocks for 2024 here .

How often does Hikma Pharmaceuticals pay dividends? What is the dividend yield for Hikma Pharmaceuticals?

Hikma Pharmaceuticals declared a dividend on Thursday, February 22nd. Shareholders of record on Thursday, March 21st will be paid a dividend of GBX 0.47 per share on Friday, May 3rd. This represents a dividend yield of 1.86%. The ex-dividend date is Thursday, March 21st. This is a positive change from the stock's previous dividend of GBX 0.25. The official announcement can be viewed at this link . Read our dividend analysis for HIK .

Is Hikma Pharmaceuticals a good dividend stock?

Hikma Pharmaceuticals (LON:HIK) pays an annual dividend of GBX 57 per share and currently has a dividend yield of 3.03%. The dividend payout ratio is 8,507.46%. Payout ratios above 75% are not desirable because they may not be sustainable. Read our dividend analysis for HIK .

What other stocks do shareholders of Hikma Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hikma Pharmaceuticals investors own include Xtrackers California Municipal Bond ETF (CA) , Endologix (ELGX) , BlackRock (BLK) , Hawkins (HWKN) , Chipotle Mexican Grill (CMG) , Aegean Marine Petroleum Network (ANW) , Athabasca Oil (ATH) , Gran Tierra Energy (GTE) , Och-Ziff Capital Management Group (OZM) and Belden (BDC) .

How do I buy shares of Hikma Pharmaceuticals?

Shares of HIK stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. Compare Top Brokerages Here .

LON:HIK

Hikma Pharmaceuticals (HIK) Share Price, News & Analysis

→ Biden replacement revealed? (From Paradigm Press) (Ad)

Free HIK Stock Alerts

GBX 1,799

+10.00 (+0.56%)

(As of 04:35 PM ET)

Compare

Today's Range: 1,763
▼
1,807
50-Day Range: 1,774
▼
2,083
52-Week Range: 1,711
▼
2,222

Volume: 374,724 shs
Average Volume: 428,627 shs
Market Capitalization: £3.99 billion

P/E Ratio: 2,685.07
Dividend Yield: 3.17%
Price Target: GBX 2,068.75

Stock Analysis Analyst Forecasts Chart Competitors Dividend Headlines Insider Trades Sustainability

Get Hikma Pharmaceuticals alerts:

Hikma Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 15.6% Upside
GBX 2,068.75 Price Target
Short Interest: N/A
Dividend Strength: Weak
Based on Four Factors
Sustainability: -2.61
Upright™ Environmental Score
News Sentiment: 0.49
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.98 out of 5 stars

2.3

Analyst's Opinion

Consensus Rating
Hikma Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Hikma Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for HIK.

0.8

Dividend Strength

Dividend Yield
Hikma Pharmaceuticals pays a meaningful dividend of 3.03%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Hikma Pharmaceuticals does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of Hikma Pharmaceuticals is 8,507.46%. Payout ratios above 75% are not desirable because they may not be sustainable.

3.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Hikma Pharmaceuticals has received a 48.26% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Abiraterone", "Cancer medication (L01)", "Isosorbide dinitrate", and "HIV medication" products. See details.
Environmental Sustainability
The Environmental Impact score for Hikma Pharmaceuticals is -2.61.

1.9

News and Social Media Coverage

News Sentiment
Hikma Pharmaceuticals has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Hikma Pharmaceuticals this week, compared to 2 articles on an average week.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Hikma Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
30.72% of the stock of Hikma Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 39.27% of the stock of Hikma Pharmaceuticals is held by institutions.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Hikma Pharmaceuticals is 2,670.15, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 135.64.
Price to Earnings Ratio vs. Sector
The P/E ratio of Hikma Pharmaceuticals is 2,670.15, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 179.87.
Price to Earnings Growth Ratio
Hikma Pharmaceuticals has a PEG Ratio of 2.38. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Hikma Pharmaceuticals has a P/B Ratio of 1.80. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

About Hikma Pharmaceuticals Stock (LON:HIK)

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.

HIK Stock Price History

30 days | 90 days | 365 days | Advanced Chart

HIK Stock News Headlines

April 17, 2024 | msn.com

Carisma Therapeutics (CARM) Price Target Decreased by 10.00% to 9.18

April 17, 2024 | americanbankingnews.com

Hikma Pharmaceuticals PLC (LON:HIK) Given Average Recommendation of "Moderate Buy" by Brokerages

April 19, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

April 14, 2024 | seekingalpha.com

HKMPY Hikma Pharmaceuticals PLC

April 11, 2024 | markets.businessinsider.com

European Stocks Close Lower Amid Uncertainty About Interest Rates

April 11, 2024 | uk.finance.yahoo.com

I’m considering these 3 undervalued pharma stocks to buy for my portfolio in April

April 9, 2024 | americanbankingnews.com

Hikma Pharmaceuticals (LON:HIK) Receives "Equal Weight" Rating from Barclays

April 7, 2024 | finance.yahoo.com

Generic Medicine Market To Reach USD 818.3 Billion By 2032, Says DataHorizzon Research

April 19, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

April 3, 2024 | msn.com

FTSE 100 Live: Index slips after topping 8000 and nearing record high, Superdry plunges

March 22, 2024 | finance.yahoo.com

Global Lidocaine Hydrochloride Market Report 2024, by Dosage Form, Application, Distribution Channel and Region

March 21, 2024 | finance.yahoo.com

Lidocaine Hydrochloride Market Forecasted to Reach USD 1.56 Billion by 2034 with Robust Growth in Asia Pacific Region

March 17, 2024 | msn.com

Big pharma shakeup in Morocco as Sanofi sells business to Hikma

March 15, 2024 | finanznachrichten.de

Hyloris Pharmaceuticals SA: Hyloris Reports Full Year Results for 2023 & Provides Business Outlook

March 14, 2024 | uk.finance.yahoo.com

Hyloris Reports Full Year Results for 2023 & Provides Business Outlook

March 13, 2024 | morningstar.com

FTSE 100 Closes Up 0.12% Ahead of U.K. Jobs Data

March 13, 2024 | markets.businessinsider.com

BioHarvest Sciences Announces New Strategic Hires for CDMO Services Business Unit

March 4, 2024 | msn.com

The 9th edition of the GCC Regulatory Affairs Pharma Summit is set to convene in Dubai in 2024, marking a significant gathering of over 400 professionals, including regional ...

February 27, 2024 | finanznachrichten.de

Hyloris Pharmaceuticals SA: Hyloris Announces Launch of Maxigesic IV in the U.S. and approval In Canada

February 27, 2024 | finance.yahoo.com

Hyloris Announces Launch of Maxigesic® IV in the U.S. and approval In Canada

February 22, 2024 | thetimes.co.uk

Hikma beats profit estimates thanks to narcolepsy drug

February 22, 2024 | msn.com

FTSE 100 Live 22 February: Lloyds results, shares start higher after Nvidia beats expectations

February 22, 2024 | lse.co.uk

TOP NEWS: Hikma boosts dividend after year of "significant progress"

February 22, 2024 | marketwatch.com

Hikma Pharmaceutical FY EPS 85c

February 21, 2024 | finance.yahoo.com

Hikma hosts White House Drug Policy Director Dr. Rahul Gupta at its Columbus, Ohio manufacturing facility

February 8, 2024 | msn.com

Higher-dose naloxone spray didn't save more lives, researchers find

February 8, 2024 | finance.yahoo.com

High-dose opioid reversal spray no better than lower dose in field, US study finds

See More Headlines

Receive HIK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 5/3 Dividend: 3/21/2024
Today: 4/19/2024
Dividend Payable: 5/03/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: LON
Sector: Medical
Industry: Drug Manufacturers - Specialty & Generic
Sub-Industry: N/A
Current Symbol: LON:HIK
CUSIP: N/A
CIK: N/A
Web: www.hikma.com
Phone: +44-20-73992760
Fax: N/A
Employees: 9,100
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: GBX 2,068.75
High Stock Price Target: GBX 2,150
Low Stock Price Target: GBX 2,000
Potential Upside/Downside: +14.6%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): GBX 0.67
Trailing P/E Ratio: 2,694.03
Forward P/E Ratio: 11.29
P/E Growth: 2.38
Net Income: £190 million
Net Margins: 6.61%
Pretax Margin: N/A
Return on Equity: 8.81%
Return on Assets: 8.46%

Debt

Debt-to-Equity Ratio: 53.92
Current Ratio: 1.57
Quick Ratio: 1.27

Sales & Book Value

Annual Sales: £2.88 billion
Price / Sales: 1.39
Cash Flow: GBX 216.46 per share
Price / Cash Flow: 8.34
Book Value: GBX 994 per share
Price / Book: 1.82

Miscellaneous

Outstanding Shares: 221,880,000
Free Float: N/A
Market Cap: £4.00 billion
Optionable: Not Optionable
Beta: 0.45

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Engineer Said Samih Taleb Darwazah (Age 67)
Executive Chairman
Comp: $2.25M
Mr. Riad Ali Mishlawi (Age 60)
CEO & Director
Comp: $885.46k
Mr. Mazen Samih Taleb Darwazah (Age 66)
Executive Vice Chairman & President of MENA
Comp: $1.85M
Mr. Khalid Waleed Hosny Al Nabilsi (Age 52)
Chief Financial Officer
Patricia Bousfield
Chief Information Officer
Mr. Guy Featherstone
Associate Director of Investor Relations
Mr. Samuel Park
General Counsel
Mr. Bassam Wael Rushdi Kanaan CFA (Age 59)
CPA, Executive Vice President of Corporate Development and M&A
Mr. Hussein Omar Arkhagha
Chief People Officer
Ms. Susan Ringdal
Executive Vice President of Strategic Planning & Global Affairs

Key Competitors

View All Competitors

Insiders

Douglas Hurt
Bought 1,500 shares on 6/6/2023
Total: £2.73 M ($1,820.00/share)

View All Insider Transactions

HIK Stock Analysis - Frequently Asked Questions

Should I buy or sell Hikma Pharmaceuticals stock right now?: 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Hikma Pharmaceuticals in the last twelve months. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" HIK shares.
View HIK analyst ratings or view top-rated stocks.
What is Hikma Pharmaceuticals' stock price target for 2024?: 6 equities research analysts have issued 1-year price targets for Hikma Pharmaceuticals' stock. Their HIK share price targets range from GBX 2,000 to GBX 2,150. On average, they predict the company's stock price to reach GBX 2,068.75 in the next year. This suggests a possible upside of 15.6% from the stock's current price.
View analysts price targets for HIK or view top-rated stocks among Wall Street analysts.
How have HIK shares performed in 2024?: Hikma Pharmaceuticals' stock was trading at GBX 1,789 at the beginning of the year. Since then, HIK stock has increased by 0.0% and is now trading at GBX 1,789.
View the best growth stocks for 2024 here.
How often does Hikma Pharmaceuticals pay dividends? What is the dividend yield for Hikma Pharmaceuticals?: Hikma Pharmaceuticals declared a dividend on Thursday, February 22nd. Shareholders of record on Thursday, March 21st will be paid a dividend of GBX 0.47 per share on Friday, May 3rd. This represents a dividend yield of 1.86%. The ex-dividend date is Thursday, March 21st. This is a positive change from the stock's previous dividend of GBX 0.25. The official announcement can be viewed at this link.
Read our dividend analysis for HIK.

Is Hikma Pharmaceuticals a good dividend stock?: Hikma Pharmaceuticals (LON:HIK) pays an annual dividend of GBX 57 per share and currently has a dividend yield of 3.03%. The dividend payout ratio is 8,507.46%. Payout ratios above 75% are not desirable because they may not be sustainable.
Read our dividend analysis for HIK.
What other stocks do shareholders of Hikma Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Hikma Pharmaceuticals investors own include Xtrackers California Municipal Bond ETF (CA), Endologix (ELGX), BlackRock (BLK), Hawkins (HWKN), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), Gran Tierra Energy (GTE), Och-Ziff Capital Management Group (OZM) and Belden (BDC).
How do I buy shares of Hikma Pharmaceuticals?: Shares of HIK stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:HIK) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Hikma Pharmaceuticals (HIK) Share Price, News & Analysis

Hikma Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Company Ownership

Earnings and Valuation

About Hikma Pharmaceuticals Stock (LON:HIK)

HIK Stock Price History

HIK Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

HIK Stock Analysis - Frequently Asked Questions

Overall MarketRank^™